Meridian Bioscience, Inc. (VIVO) Expected to Post Quarterly Sales of $53.63 Million

Equities research analysts predict that Meridian Bioscience, Inc. (NASDAQ:VIVO) will post sales of $53.63 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Meridian Bioscience’s earnings, with the highest sales estimate coming in at $54.31 million and the lowest estimate coming in at $52.57 million. Meridian Bioscience posted sales of $52.28 million during the same quarter last year, which would indicate a positive year over year growth rate of 2.6%. The firm is expected to report its next quarterly earnings report on Thursday, January 24th.

On average, analysts expect that Meridian Bioscience will report full year sales of $216.85 million for the current fiscal year, with estimates ranging from $212.63 million to $219.83 million. For the next year, analysts forecast that the firm will post sales of $228.84 million, with estimates ranging from $228.33 million to $229.36 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Meridian Bioscience.

Meridian Bioscience (NASDAQ:VIVO) last released its earnings results on Thursday, November 8th. The company reported $0.20 EPS for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.04. The company had revenue of $213.60 million during the quarter, compared to analysts’ expectations of $51.11 million. Meridian Bioscience had a return on equity of 16.97% and a net margin of 11.49%. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.15 EPS.

VIVO has been the subject of a number of research analyst reports. BidaskClub cut Meridian Bioscience from a “hold” rating to a “sell” rating in a research note on Wednesday, August 8th. ValuEngine upgraded Meridian Bioscience from a “hold” rating to a “buy” rating in a research note on Monday, October 29th. Finally, Zacks Investment Research upgraded Meridian Bioscience from a “hold” rating to a “strong-buy” rating and set a $23.00 target price for the company in a research note on Saturday. One equities research analyst has rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Meridian Bioscience presently has an average rating of “Buy” and an average target price of $19.50.

Shares of VIVO traded up $0.09 on Monday, reaching $19.72. The stock had a trading volume of 434,428 shares, compared to its average volume of 290,581. The stock has a market cap of $719.87 million, a PE ratio of 26.65 and a beta of 0.54. The company has a quick ratio of 3.89, a current ratio of 5.73 and a debt-to-equity ratio of 0.27. Meridian Bioscience has a 12-month low of $13.53 and a 12-month high of $19.84.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 30th. Investors of record on Monday, November 19th will be given a dividend of $0.125 per share. This represents a $0.50 dividend on an annualized basis and a yield of 2.54%. The ex-dividend date of this dividend is Friday, November 16th. Meridian Bioscience’s dividend payout ratio (DPR) is presently 67.57%.

In related news, Director John Mcilwraith acquired 2,000 shares of Meridian Bioscience stock in a transaction that occurred on Friday, August 24th. The stock was bought at an average price of $15.63 per share, with a total value of $31,260.00. Following the transaction, the director now directly owns 6,000 shares in the company, valued at $93,780. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.70% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. Macquarie Group Ltd. bought a new position in Meridian Bioscience during the 2nd quarter valued at approximately $119,000. Piedmont Investment Advisors LLC bought a new stake in shares of Meridian Bioscience in the 2nd quarter worth $157,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Meridian Bioscience in the 3rd quarter worth $151,000. Itau Unibanco Holding S.A. bought a new stake in shares of Meridian Bioscience in the 2nd quarter worth $162,000. Finally, Robecosam AG increased its holdings in shares of Meridian Bioscience by 194.3% in the 3rd quarter. Robecosam AG now owns 10,300 shares of the company’s stock worth $153,000 after purchasing an additional 6,800 shares in the last quarter. 88.56% of the stock is owned by institutional investors.

About Meridian Bioscience

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Featured Article: Initial Public Offering (IPO)

Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with's FREE daily email newsletter.

Leave a Reply